Please wait a minute...
文章检索
预防医学  2016, Vol. 28 Issue (12): 1221-1225    
  论著 本期目录 | 过刊浏览 | 高级检索 |
2型糖尿病患者非酒精性脂肪性肝病与性激素水平的关系
汪凌霄1, 李勇杰1, 李红2
1. 绍兴市中心医院内分泌科,浙江绍兴 312030;
2.浙江大学医学院附属邵逸夫医院
A study on the association between nonalcoholic fatty liver diseaseand the levels of sex hormones among patientswith type 2 diabetes mellitus
WANG Ling-xiao, LI Yong-jie, LI Hong
Department of Endocrinology, Shaoxing Central Hospital,Shaoxing,Zhejiang 312030, China,
全文: PDF(570 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2型糖尿病(T2DM)患者非酒精性脂肪性肝病(NAFLD)与性激素水平的关系。方法 选取2010年3月—2013年10月在绍兴市中心医院内分泌科住院的T2DM患者256例,根据是否合并NAFLD分为NAFLD组和非NAFLD组,比较两组患者性激素和糖脂代谢指标水平差异,采用多因素Logistic回归模型分析T2DM患者NAFLD患病的影响因素。结果 256例T2DM患者的NAFLD检出率为56.25%,男性检出率为59.15%,女性为52.63%,差异无统计学意义(P>0.05)。男性患者中,NAFLD组睾酮(T)水平为(3.78±1.13)ng/mL,低于非NAFLD组的(4.61±1.55)ng/mL(P<0.05);NAFLD组雌二醇(E2)水平为(22.24±12.88)pg/mL,高于非NAFLD组的(17.84±8.72)pg/mL(P<0.05)。女性患者中,NAFLD组E2水平为(19.83±8.61)pg/mL,低于非NAFLD组的(26.32±16.85)pg/mL(P<0.05)。多因素Logistic回归分析结果显示,T(OR=0.660,95%CI:0.495~0.880)和E2(OR=0.958,95%CI:0.922~0.996)水平分别是男、女性T2DM患者患NAFLD的保护因素,而E2(OR=1.042,95%CI:1.001~1.085)水平是男性T2DM患者患NAFLD的危险因素。结论 T2DM合并NAFLD患者存在性激素紊乱;T和E2分别是男、女T2DM患者患NAFLD的保护因素。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
汪凌霄
李勇杰
李红
关键词 2型糖尿病非酒精性脂肪性肝病性激素胰岛素抵抗    
AbstractObjective To explore the association between non-alcoholic fatty liver disease(NAFLD) and the levels of sex hormones among patients with type 2 diabetes mellitus(T2DM).Methods The prevalence of NAFLD in 256 patients in Shaoxing Central Hospital from Match 2010 to October 2013 with type 2 diabetes were calculated. According to with or without NAFLD, the T2DM patients were divided into NAFLD group and non-NAFLD group. The levels of sex hormones, glucose and lipid were detected. The difference between the two groups was compared and the relationship between NAFLD and sex hormone were explored. Results The prevalence rate of NAFLD in patients with type 2 diabetes was 56.25%, but the prevalence of NAFLD was not different between different genders. Patients with NAFLD have obvious sex hormone disorder, and testosterone(T) in NAFLD group were lower than those in non-NAFLD group and estradiol (E2) in NAFLD group were higher than those in non-NAFLD group among males.E2in NAFLD group were lower than those in non-NAFLD group among females.Further logisitic regression analysis showed that T and E2were protective factors of NAFLD in males and females, while E2was the risk factors of NAFLD in males. Conclusion For patients with NAFLD in type 2 diabetes, the dominant sex hormone is a protective factor for the formation of NAFLD.
Key wordsType 2 diabetes mellitus (T2DM)    Nonalcoholic fatty liver disease (NAFLD)    Sex hormones    Insulin resistance
收稿日期: 2016-03-19          
中图分类号:  R587.1  
  R575.5  
作者简介: 汪凌霄,本科,副主任医师,主要从事内分泌临床研究工作
通信作者: 李红,E-maillihongheyi@126.com   
引用本文:   
汪凌霄, 李勇杰, 李红. 2型糖尿病患者非酒精性脂肪性肝病与性激素水平的关系[J]. 预防医学, 2016, 28(12): 1221-1225.
WANG Ling-xiao, LI Yong-jie, LI Hong. A study on the association between nonalcoholic fatty liver diseaseand the levels of sex hormones among patientswith type 2 diabetes mellitus. Preventive Medicine, 2016, 28(12): 1221-1225.
链接本文:  
https://www.zjyfyxzz.com/CN/      或      https://www.zjyfyxzz.com/CN/Y2016/V28/I12/1221
[1] BELLENTANI S, SCAGLIONI F, MARINO M, et al. Epidemiology of non-alcoholic fatty liver disease[J]. Dig Dis, 2010, 28(1):155-161.
[2]TARGHER G, DAY C P, BONORA E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 363(14):1341-1350.
[3]MATTIAS EKSTEDT,HANNES HAGSTRM, NASR P,et al.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology,2015, 61(5):1547-1554.
[4]张艳, 郭传勇. 非酒精性脂肪性肝病发病机制及其相关基因研究进展[J]. 实用肝脏病杂志, 2013,16(4):375-377.
[5]艾萍,廖映红.2型糖尿病合并非酒精性脂肪性肝病与血脂代谢紊乱的关系[J].中国老年学杂志,2016,36(2):327-330.
[6]中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南[J]. 中国肝脏病杂志:电子版, 2010, 15(3):229-232.
[7]ANSTEE Q M, MCPHERSON S, Day C P. How big a problem is non-alcoholic fatty liver disease?[J]. British Medical Journal-Clinical Research Edition, 2011, 343(8): d3897.
[8]李勇杰, 苏宏业, 李圣琦. 2型糖尿病患者非酒精性脂肪肝检出率及临床特点[J]. 广西医学, 2012, 34(1):86-88.
[9]GUTIERREZ-GROBE Y, PONCIANO-RODRIGUEZ G, RAMOS M H, et al. Prevalence of non-alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens[J]. Ann Hepatol, 2010, 9(4):402-409.
[10]VOLZKE H, AUMANN N, KREBS A, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men[J]. Int J Androl,2010,33(1):45-53.
[11]江小平, 李芳萍. 男性2型糖尿病患者伴非酒精性脂肪肝病的性激素变化——附53例报告[J]. 新医学, 2010, 41(8):508-510.
[12]周丽荣,马艳.2型糖尿病合并非酒精性脂肪性肝病患者的胰岛功能变化[J].医学综述, 2016,22(16): 3263-3266.
[13]BASARIA S, MULLER D C, CARDUCCI M A, et al.Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy[J]. Cancer, 2006, 106(3):581-588.
[14]范小芬,邓银泉,陈玖,等.非酒精性脂肪性肝病不同中医证型与血清TNF-α、IL-6水平的关系研究[J].西部中医药,2016,29(1):5-7.
[15]王亚东,张英泽,赵彩彦,等. 性激素在非酒精性脂肪性肝病发病机制中的作用[J]. 中华肝脏病杂志,2012,20(5):398-400.
[16]陈艳丽.NAFLD患者肠道菌群改变与膳食因素及血清LPS、IL-18、IL-1β的相关性研究[D].安徽医科大学,2015.
[17]范世宏,毛玉山,麦一峰.2型糖尿病合并非酒精性脂肪肝与血清脂联素的相关性研究[J]. 预防医学,2016,28(10):973-976.
[18]唐东华,姚起新,亓竹青,等. 17β-雌二醇上调去卵巢胰岛素抵抗大鼠骨骼肌中胰岛素受体的表达[J]. 中华内分泌代谢杂志,2010,26(8):695-698.
[19]王晓琳,章志建,陆炎,等.雌激素在肝脏糖脂代谢中的作用机制研究[C]//中华医学会第十一次全国内分泌学学术会议论文汇编,2012.
[20]邢莉莉,舒静,方素华. 雌激素及其受体在能量代谢中的作用[J]. 中华妇产科杂志,2013,48(7):548-550.
[1] 吴成慧, 彭艳红, 张可, 朱维晔, 邓亮, 谭玲玲, 瞿丹丹, 米秋香. 中青年2型糖尿病患者益处发现的影响因素分析[J]. 预防医学, 2026, 38(1): 31-35.
[2] 陆杰, 张柯, 吴雅, 王玥, 张玥, 陆叶, 吴周理, 任志华, 黄艺文. 肥胖指标预测2型糖尿病患者心脑血管疾病的效果比较[J]. 预防医学, 2025, 37(9): 886-891.
[3] 张凯慧, 李婉玲, 王彦兴, 安愿. 老年2型糖尿病患者心理灵活性、运动自我效能在衰弱与社会疏离间的中介效应分析[J]. 预防医学, 2025, 37(8): 783-788.
[4] 刘明坤, 张丰香, 韩彩静, 王霞, 陈世坤, 金梅, 孙金月. 2型糖尿病患者周围神经病变风险预测模型研究[J]. 预防医学, 2025, 37(7): 692-696.
[5] 俞丹丹, 杨加丽, 张雅萍, 许慧琳, 何丹丹, 李俊. 2型糖尿病共病患者空腹血糖波动轨迹的影响因素研究[J]. 预防医学, 2025, 37(6): 562-567,572.
[6] 李美琳, 周梦姣, 吴佳芸, 喻喆, 孔利萍. 老年男性2型糖尿病患者合并肌少症的影响因素分析[J]. 预防医学, 2025, 37(6): 588-592.
[7] 陆丽君, 袁磊, 李殿江, 卢昆, 朱怡萱, 王志勇, 刘思浚. 老年2型糖尿病患者自我效能、自我管理行为在抑郁症状与血糖控制间的中介效应分析[J]. 预防医学, 2025, 37(5): 455-459.
[8] 王英杰 综述, 孙高峰, 审校. 2型糖尿病预测模型研究进展[J]. 预防医学, 2025, 37(4): 369-372,377.
[9] 孙霞, 但玲英, 郑鹏, 陈薪伊. 2型糖尿病患者脂肪因子与糖尿病视网膜病变的关联研究[J]. 预防医学, 2025, 37(3): 248-252.
[10] 陈海苗, 马岩, 刘明奇, 马珊珊, 李军, 方益荣. 儿童期肥胖与2型糖尿病、冠心病的孟德尔随机化研究[J]. 预防医学, 2025, 37(3): 307-311.
[11] 文进博, 张婷, 赵倩, 刘景, 孙中明, 侯建斌, 陆正权, 许雨婷, 马新雄, 潘恩春. 2型糖尿病患者运动处方干预效果评价[J]. 预防医学, 2025, 37(12): 1211-1216.
[12] 吴梓敬, 李纪新, 邱林杰, 任燕, 李美洁, 邹姹姹, 张晋. 身体形态指数和身体圆度指数预测非肥胖人群非酒精性脂肪性肝病的效果比较[J]. 预防医学, 2025, 37(12): 1222-1227.
[13] 杨丽雅, 杜厉英, 张亚当, 姜灵芝. 2型糖尿病患者西格列汀联合二甲双胍与门冬胰岛素联合二甲双胍干预效果比较[J]. 预防医学, 2025, 37(10): 1054-1058.
[14] 王英杰, 孙高峰, 赵娥, 田原. 2017—2021年乌鲁木齐市2型糖尿病患者管理指标分析[J]. 预防医学, 2025, 37(1): 92-95.
[15] 崔彦泽, 张玲, 蒋璐, 李慧敏, 王硕. 衰弱与2型糖尿病的孟德尔随机化研究[J]. 预防医学, 2024, 36(9): 786-789.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed